Effect of TNF-α genetic variants and CCR5Δ32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Veloso, Sergi ^a,b,c   Olona, Montserrat ^a,b,c   García, Felipe ^d   Domingo, Pere ^e,f   Alonso Villaverde, Carlos ^b,c,g   Broch, Montserrat ^b,c,h   Peraire, Joaquim ^a,b,c   Viladés, Consuelo ^a,b,c   Plana, Montserrat ^d   Pedrol, Enric ⁱ   López Dupla, Miguel ^a,b,c   Aguilar, Carmen ^a,b,c,h   Gutiérrez, Mar ^e   Leon, Agathe ^d   Tasias, Mariona ⁱ   Ma Gatell, Josep ^d,j   Richart, Cristóbal ^a,b,c,h   Vidal, Francesc ^a,b,c  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^h Instituto de Salud Carlos III   (Spain)

ⁱ Hospital de Sant Pau i Santa Tecla   (Spain)

^j UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VIREMIA; GENETIC PREDISPOSITION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; VULNERABLE POPULATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CCR5; TUMOR NECROSIS FACTOR-ALPHA; VULNERABLE POPULATIONS;

EID: 77951233873     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-63     Document Type: Article

References (43)

1. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008, 214:149-160. 10.1002/path.2287, 18161752.
2. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon M. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol 1998, 160:3194-3206.
3. Herbelin G, Aziz Khan K. Is HIV infection a TNF receptor signalling-driven disease?. Trends Immunol 2007, 29:61-67.
4. Domingo P, Vidal F, Domingo JC, Veloso S, Sambeat MA, Torres F, Sirvent JJ, Vendrell J, Matias-Guiu X, Richart C, . HIV-FRS Study Group Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 2005, 35:771-780. 10.1111/j.1365-2362.2005.01576.x, 16313254, HIV-FRS Study Group.
5. Bouma G, Crusius JBA, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, Giphart MJ, Schreuder GM, Meuwissen SG, Peña AS. Secretion of tumour necrosis factor and lymphotoxin in relation to polymorphisms in TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996, 43:456-463. 10.1046/j.1365-3083.1996.d01-65.x, 8668926.
6. Hajeer AH, Hutchinson IV. Influence of TNFα gene polymorphisms on TNFα production and disease. Human Immunology 2001, 62:1191-1199. 10.1016/S0198-8859(01)00322-6, 11704281.
7. Wilson AG, de Vries N, Pociot F, di Giovine FS, Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8 and DR3 alleles. J Exp Med 1993, 177:557-560. 10.1084/jem.177.2.557, 2190902, 8426126.
8. D'Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994, 39:150-154.
9. Auguet T, Vidal F, López-Dupla M, Broch M, Gutiérrez C, Olona M, Oltra C, Aguilar C, González E, Quer JC, Sirvent JJ, Richart C. A study on the TNF-α system in Caucasian Spanish patients with alcoholic liver disease. Drug Alcohol Depend 2008, 92:91-99. 10.1016/j.drugalcdep.2007.07.008, 17728075.
10. Khoo SH, Pepper L, Snowden N, Hajeer AH, Vallely P, Wilkins EG, Mandal BK, Ollier WE. Tumor necrosis factor c2 micro satellite allele is associated with the rate of HIV progression. AIDS 1997, 11:423-428. 10.1097/00002030-199704000-00004, 9084788.
11. Knuchel MC, Spira TJ, Neumman AU, Xiao L, Rudolph DL, Phair J, Wolinsky SM, Koup RA, Cohen OJ, Folks TM, Lal RB. Analysis of a biallelic polymorphism in the tumor necrosis factor alpha promoter and HIV type 1 disease progression. AIDS Res Hum Retroviruses 1998, 14:305-309. 10.1089/aid.1998.14.305, 9519891.
12. Konenkov VI, Smolnikova MV. Polymorphism of promotor sites of Interleukins-4 and -10 and tumour necrosis factor-α genes in HIV-infected patients. Bull Experiment Biol Med 2002, 4:389-391.
13. Wang C, Song W, Lovashevsky E, Wilson CM, Douglas SD, Mytilineos J, Schoenbaum EE, Tang J, Kaslow RA. Cytokine and chemokine gene polymorphisms among ethnically diverse North Americans with HIV-1 infection. J Acquir Immune Defic Syndr 2004, 35:446-454. 10.1097/00126334-200404150-00002, 15021309.
14. Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, Gomo E, Butterworth AE, Pedersen BK, Ostrowski SR, Gerstoft J, Ullum H. Reduced mortality and CD4 cell loss among carriers of the interleukin-10-1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS 2007, 21:2283-2291. 10.1097/QAD.0b013e3282f153ed, 18090276.
15. Brinkmann BM, Keet IP, Miedema F, Verweij CL, Klein MR. Polymorphisms within the human tumor necrosis factor-alpha promoter region in human immunodeficiency virus type-1 seropositive persons. J Infect Dis 1997, 175:188-190.
16. Delgado JC, Leung JY, Baena A, Clavijo OP, Vittinghoff E, Buchbinder S, Wolinsky S, Addo M, Walker BD, Yunis EJ, Goldfeld AE. The -1063/-862-linked TNF promoter single-nucleotide polymorphisms are associated with the inability to control HIV-1 viremia. Immunogenetics 2003, 55:497-501. 10.1007/s00251-003-0604-7, 14517700.
17. Limou S, Le Clerck S, Coulonges C, Carpentier W, Dina C, Delaneau O, Labib T, Taing L, Sladek R, Deveau C, Ratsimandresy R, Montes M, Spadoni JL, Lelièvre JD, Lévy Y, Therwath A, Schächter F, Matsuda F, Gut I, Froguel P, Delfraissy JF, Hercberg S, Zagury JF, . ANRS Genomic Group Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS genomewide association study 02). J Infect Dis 2009, 199:419-426. 10.1086/596067, 19115949, ANRS Genomic Group.
18. Petrucci A, Dorrucci M, Alliegro MB, Pezzotti P, Rezza G, Sinicco A, Lazzarin A, Angarano G. How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study. Italian Seroconversion Study Group. J Acquir Immune Defic Syndr 1997, 14:243-248.
19. Bailey JR, Lassen KJ, Yang HC, Quinn TC, Ray SC, Blankson JN, Siliciano RF. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006, 80:4758-4770. 10.1128/JVI.80.10.4758-4770.2006, 1472047, 16641269.
20. Peraire J, Vidal F, Plana M, Domingo P, Coll B, Viladés C, Garcia F, Veloso S, Gatell JM, Broch M. Polymorphism in the 3'untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression. AIDS 2007, 23:891-893.
21. Viladés C, Broch M, Plana M, Domingo P, Alonso-Villaverde C, Pedrol E, Knobel H, Dalmau D, Peraire J, Gutiérrez C, López A, Sambeat MA, Olona M, Garcia F, Richart C, Gatell JM, Vidal F, . Chemokines and Long-Term Nonprogressors Study Group Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection. J Acquir Immune Defic Syndr 2007, 44:132-138. 10.1097/QAI.0b013e31802b3147, 17091019, Chemokines and Long-Term Nonprogressors Study Group.
22. Ioannidis JPA, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA, Eugen-Olsen J, Gallart T, Katzenstein TL, Kostrikis LG, Kuipers H, Louie LG, Mallal SA, Margolick JB, Martinez OP, Meyer L, Michael NL, Operskalski E, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Stewart GJ, Theodorou ID, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury JF, O'Brien TR, . International Meta-Analysis of HIV Host Genetics Effects of CCR5, CCR2-64I and SDF-1 3'A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001, 135:782-795. International Meta-Analysis of HIV Host Genetics.
23. Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL. CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41(RR-17):1-20.
24. Vidal F, Peraire J, Domingo P, Broch M, Cairó M, Pedrol E, Montero M, Viladés C, Gutiérrez C, Sambeat MA, Fontanet A, Dalmau D, Deig E, Knobel H, Sirvent JJ, Richart C, Veloso S, Saumoy M, López-Dupla M, Olona M, Cadafalch J, Fuster M, Ochoa A, Soler A, Guelar A, González J, . Chemokines and Long-Term Nonprogressive HIV-1 Infection Study Group Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years. J Acquir Immune Defic Syndr 2006, 41:17-22. 10.1097/01.qai.0000188335.86466.ea, 16340468, Chemokines and Long-Term Nonprogressive HIV-1 Infection Study Group.
25. McDermott D, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA, Boatin BA, Leitman SF, Detels R, Hajeer AH, Murphy PM. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000, 14:821-826. 10.1097/00002030-200012010-00006, 10839590.
26. Soriano A, Martinez C, Garcia F, Plana M, Palou E, Lejeune M, Aróstegui JI, De Lazzari E, Rodriguez C, Barrasa A, Lorenzo JI, Alcamí J, del Romero J, Miró JM, Gatell JM, Gallart T. Plasma stromal cell-derived factor (SDF)-1 levels, SDF-1 3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis 2002, 186:922-931. 10.1086/343741, 12232832.
27. Soriano A, Lozano F, Oliva H, García F, Nomdedéu M, De Lazzari E, Rodríguez C, Barrasa A, Lorenzo JI, Del Romero J, Plana M, Miró JM, Gatell JM, Vives J, Gallart T. Polymorphisms in the interleukin-4 receptor α chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics 2005, 57:644-654. 10.1007/s00251-005-0041-x, 16189667.
28. Li N, Stephens M. Modelling linkage disequilibrium, and identifying recombination hotspots using SNP data. Genetics 2003, 165:2213-2233. 1462870, 14704198.
29. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989. 10.1086/319501, 1275651, 11254454.
30. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing data imputation. Am J Hum Genet 2005, 76:449-462. 10.1086/428594, 1196397, 15700229.
31. Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?. AIDS 1991, 5:1405-1417. 10.1097/00002030-199112000-00001, 1814326.
32. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001, 12:133-150.
33. Hendel H, Winkler C, An P, Roemer-Binns E, Nelson G, Haumont P, O'Brien S, Khalilli K, Zagury D, Rappaport J, Zagury JF. Validation of genetic case-control studies in AIDS and aplication to the CX3CR1 polymorphism. J Acquir Immune Defic Syndr 2001, 26:507-511.
34. Chakravati A. Kinship: Race relations. Nature 2009, 457:380-381. 10.1038/457380a, 19158772.
35. Quasney MW, Zhang Q, Sargent S, Mynatt M, Glass J, McArthur J. Increased frequency of the tumor necrosis factor-α-308A allele in adults with human immunodeficiency virus dementia. Ann Neurol 2001, 50:167-172.
36. Pemberton LA, Stone E, Price P, van Bockxmeer F, Brew BJ. The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV-1-associated dementia. HIV Med 2008, 9:677-680. 10.1111/j.1468-1293.2008.00614.x, 18631256.
37. Sato-Matsumara KC, Berger J, Hainfeller JA, Mazal P, Budka H. Development of HIV encephalitis and TNF-α regulatory elements. J Neuroimmunol 1998, 91:89-92. 10.1016/S0165-5728(98)00161-1, 9846823.
38. Diaz-Arrastia R, Gong Y, Kelly CJ, Gelman BB. Host genetic polymorphisms in human immunodeficiency virus-related neurologic disease. J Neurovirol 2004, 10(Suppl 1):67-73.
39. Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA, Wyvill K, Steinberg SM, Kovacs J, Blauvelt A, Yarchoan R, Chanock SJ. An IL-6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000, 96:2562-2567.
40. Price P, Morahan G, Huang D, Stone E, Cheong KY, Castley A, Rodgers M, McIntyre MQ, Abraham LJ, French MA. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002, 16:2043-2047. 10.1097/00002030-200210180-00009, 12370503.
41. Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, Unutmaz D, Benson CA, Ritchie MD, Landay A, . AIDS Clinical Trials Group Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trials Group Study. J Infect Dis 2006, 194:1098-1107. 10.1086/507313, 16991084, AIDS Clinical Trials Group.
42. Rappaport J, Cho YY, Hendel H, Scwartz EJ, Schachter F, Zagury JF. 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes. Lancet 1997, 349:922-923. 10.1016/S0140-6736(05)62697-9, 9093257.
43. Winkler CA, Hendel H, Carrington M, Smith MW, Nelso GW, O'Brien SJ, Phair J, Vlahov D, Jacobson LP, Rappaport J, Vasilescu A, BertinMaghit S, An P, Lu W, Andrieu JM, Schächter F, Therwath A, Zagury JF. Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. J Acquir Immune Defic Syndr 2004, 37:1534-1538. 10.1097/01.qai.0000127353.01578.63, 15602133.